These findings provide new insights for the use of apatinib in postoperative chemotherapy of recurrent gliomas and present a novel strategy for the treatment of recurrent gliomas that involves targeting the THBS1/MYH9 axis. Here, THBS1 is linked to central nervous system cancer.